Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...

Randomized, placebo-controlled trial finds that low-dose semaglutide reduces amount of alcohol consumption, alcohol cravings, and heavy drinking days. Reductions in cigarettes per day were also seen.

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Weight-loss jabs such as Ozempic are being hailed as a potential breakthrough in the fight against obesity. Demand, fuelled ...

injection, and nasal spray. This development further strengthens Hydreight’s commitment to providing innovative and accessible wellness solutions through its national telehealth network. This launch ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.